drugset / Trial / NCT00449436

Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults

NCT00449436

Phase 4 Completed 152 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

The current goal of antiretroviral therapy is to use a potent regimen that will suppress plasma viral load and maintain this suppression as long as possible. However, for most patients treated with such potent regimen, several problems can limit their long term effectiveness and contribute to incomplete viral suppression. These problems include poor tolerability, metabolic toxic effects. In order to avoid common problems as toxicity it might be interested to simplify treatment with fewer toxicity, lower pill burden. In this study we will evaluate the safety and efficacy of a simplification treatment with TRIZIVIR in long term after a Boosted PI or NNRTI containing regimen as first line therapy.

Timeline

Start
2005-01-10
Primary completion
2007-12-12
Completion
2007-12-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Trizivir Unknown